Skip to main content

NIH consensus development statement on hydroxyurea treatment for sickle cell disease.

Publication ,  Conference
Brawley, OW; Cornelius, LJ; Edwards, LR; Gamble, VN; Green, BL; Inturrisi, CE; James, AH; Laraque, D; Mendez, MH; Montoya, CJ; Pollock, BH ...
Published in: NIH Consens State Sci Statements
February 27, 2008

National Institutes of Health consensus and state-of-the-science statements are prepared by independent panels of health professionals and public representatives on the basis of (1) the results of a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality (AHRQ), (2) presentations by investigators working in areas relevant to the conference questions during a 2-day public session, (3) questions and statements from conference attendees during open discussion periods that are part of the public session, and (4) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the U.S. Government.The statement reflects the panel's assessment of medical knowledge available at the time the statement was written. Thus, it provides a "snapshot in time" of the state of knowledge on the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.

Duke Scholars

Published In

NIH Consens State Sci Statements

EISSN

1553-0779

Publication Date

February 27, 2008

Volume

25

Issue

1

Start / End Page

1 / 30

Location

United States

Related Subject Headings

  • Male
  • Infant
  • Hydroxyurea
  • Humans
  • Female
  • Child, Preschool
  • Child
  • Biomedical Research
  • Antisickling Agents
  • Anemia, Sickle Cell
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brawley, O. W., Cornelius, L. J., Edwards, L. R., Gamble, V. N., Green, B. L., Inturrisi, C. E., … Schori, M. (2008). NIH consensus development statement on hydroxyurea treatment for sickle cell disease. In NIH Consens State Sci Statements (Vol. 25, pp. 1–30). United States.
Brawley, Otis W., Llewellyn J. Cornelius, Linda R. Edwards, Vanessa Northington Gamble, Bettye L. Green, Charles E. Inturrisi, Andra H. James, et al. “NIH consensus development statement on hydroxyurea treatment for sickle cell disease.” In NIH Consens State Sci Statements, 25:1–30, 2008.
Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi CE, et al. NIH consensus development statement on hydroxyurea treatment for sickle cell disease. In: NIH Consens State Sci Statements. 2008. p. 1–30.
Brawley, Otis W., et al. “NIH consensus development statement on hydroxyurea treatment for sickle cell disease.NIH Consens State Sci Statements, vol. 25, no. 1, 2008, pp. 1–30.
Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi CE, James AH, Laraque D, Mendez MH, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. NIH consensus development statement on hydroxyurea treatment for sickle cell disease. NIH Consens State Sci Statements. 2008. p. 1–30.

Published In

NIH Consens State Sci Statements

EISSN

1553-0779

Publication Date

February 27, 2008

Volume

25

Issue

1

Start / End Page

1 / 30

Location

United States

Related Subject Headings

  • Male
  • Infant
  • Hydroxyurea
  • Humans
  • Female
  • Child, Preschool
  • Child
  • Biomedical Research
  • Antisickling Agents
  • Anemia, Sickle Cell